Richard Bogan, MD
Pulmonary Disease · Columbia, SCNPI 1538347661
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $654,928 of the $1,070,710 with a category attached, or 61.2%. Jazz Pharmaceuticals Inc. accounts for 62.5% of it on its own, with 31 other manufacturers making up the rest. Among pulmonary disease clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,156 payments — averaging $926.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$669K
- Axsome Therapeutics, Inc.$119K
- Harmony Biosciences LLC$82K
- Idorsia Pharmaceuticals US Inc$68K
- Takeda Pharmaceuticals U.S.A., Inc.$59K
- Eisai Inc.$46K
- plus $28K from 26 others
Across 1,387 payments — averaging $2912.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$994K
- Jazz Pharmaceuticals Inc.$918K
- Alkermes, Inc.$647K
- Livanova USA, Inc.$524K
- Irhythm Technologies, Inc.$244K
- Avadel CNS Pharmaceuticals, LLC$215K
- plus $496K from 12 others
What the payments were for
- Consulting fees$283,53226%
- Speaking & faculty fees$654,92861%
- Travel & lodging$107,37310%
- Food & beverage$24,2942%
- Education$5840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 663 | $669,353 |
| Axsome Therapeutics, Inc. | 123 | $118,628 |
| Harmony Biosciences LLC | 103 | $81,517 |
| Idorsia Pharmaceuticals US Inc | 49 | $68,258 |
| Takeda Pharmaceuticals U.S.A., Inc. | 40 | $58,506 |
| Eisai Inc. | 68 | $46,079 |
| Alkermes, Inc. | 9 | $18,549 |
| Daiichi Sankyo Inc. | 7 | $2,832 |
| Pear Therapeutics (US), Inc. | 1 | $1,700 |
| Merck | 24 | $1,520 |
| Amneal Pharmaceuticals LLC | 1 | $1,500 |
| Tris Pharma Inc | 1 | $500 |
| Avadel CNS Pharmaceuticals, LLC | 12 | $326 |
| Sanofi | 4 | $210 |
| Fisher & Paykel Healthcare Inc | 5 | $146 |
| Noctrix Health, Inc. | 2 | $141 |
| AstraZeneca | 1 | $125 |
| Arbor Pharmaceuticals, Inc. | 9 | $123 |
| Resmed Corp | 6 | $103 |
| Inspire Medical Systems, Inc. | 5 | $95 |
| Philips North America LLC | 2 | $89 |
| Azurity Pharmaceuticals, Inc. | 5 | $80 |
| Vanda Pharmaceuticals Inc. | 3 | $76 |
| Supernus Pharmaceuticals, Inc. | 3 | $74 |
| Lilly USA, LLC | 2 | $37 |
| Aytu Biopharma, Inc. | 2 | $31 |
| Irhythm Technologies, Inc. | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Novartis | 1 | $17 |
| Corium, LLC | 1 | $15 |
| Almatica Pharma LLC | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,070,710 in reported general payments places this provider in the 95th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 61 | $996,998 |
| WakixPitolisant Hcl | 48 | $726,288 |
| Sodium Oxybate | 39 | $554,593 |
| HetliozTasimelteon | 12 | $291,422 |
| XyremSodium Oxybate | 17 | $265,008 |
| LumryzSodium Oxybate | 21 | $256,820 |
| SunosiSolriamfetol Hcl | 64 | $53,906 |
| BelsomraSuvorexant | 79 | $35,506 |
| Modafinil | 113 | $15,943 |
| HorizantGabapentin Enacarbil | 14 | $7,829 |
| DayvigoLemborexant | 16 | $5,107 |
| Gabapentin | 330 | $3,739 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 114 | $3,535 |
| Armodafinil | 57 | $3,219 |
| Trazodone Hcl | 76 | $1,871 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Harmony Biosciences LLCWakix | $81,517 | $726,28848 claims |
| Vanda Pharmaceuticals Inc.Hetlioz | $76 | $291,42212 claims |
| Avadel CNS Pharmaceuticals, LLCLumryz | $326 | $256,82021 claims |
| Axsome Therapeutics, Inc.Sunosi | $118,628 | $53,90664 claims |
| MerckBelsomra | $1,520 | $35,50679 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $123 | $7,82914 claims |
| Eisai Inc.Dayvigo | $46,079 | $5,10716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Columbia
- Laura HerpelColumbia$254K
- Jake KriegmdColumbia$112K
- Mark MaysonColumbia$86K
- Karla Cruz MorelColumbia$74K
- Gregory FeldmanColumbia$73K
- Carlton CauthenColumbia$17K
- Liang ZhaColumbia$10K
- Todd GandyColumbia$10K
- Matthew VarnerColumbia$9K
- Abhijit RavalAnderson$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.